Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares saw strong trading volume on Friday . 308,340 shares were traded during trading, an increase of 154% from the previous session’s volume of 121,183 shares.The stock last traded at $10.58 and had previously closed at $10.65.

A number of analysts recently issued reports on the stock. Piper Jaffray Cos. set a $23.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Thursday. Zacks Investment Research raised shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Finally, Needham & Company LLC reissued a “buy” rating and set a $30.00 target price (up previously from $28.00) on shares of Collegium Pharmaceutical in a research report on Thursday, May 26th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $28.25.

The stock’s market capitalization is $248.68 million. The stock’s 50 day moving average is $12.27 and its 200 day moving average is $16.13.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.29. On average, analysts forecast that Collegium Pharmaceutical Inc. will post ($3.76) EPS for the current fiscal year.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.